RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal

Item

http://www.wikidata.org/entity/Q34478729

Q34478729

about

Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials.Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.Variation in the Use of Chemoradiotherapy for Stage II and III Anal Cancer: Analysis of the National Cancer Data Base.Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.Concurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer-acute toxicity and treatment outcome The outcomes of therapeutic decision in lower 3rd rectal cancer patients Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity.Technical aspects of radiation therapy for anal cancer.Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas.Therapeutic approaches in the management of locally advanced rectal cancer.Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer.Interstitial high-dose rate brachytherapy as boost for anal canal cancer.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy Clinical experience of SIB-IMRT in anal cancer and selective literature review.Comparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancer Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.Whole pelvic intensity-modulated radiotherapy for gynecological malignancies: A review of the literature.Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy.Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base.Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience.Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal.Sphincter preservation in anal cancer: a brief review.Radiation quality, like art, consists in drawing the line somewhere.

P2860

Q28082745-8F8D5CBE-6868-4B73-AB4F-73E646DE23FC Q30235359-F74EA778-CC85-40C6-98AF-E955A36AF574 Q30409533-3F257358-CB97-498B-AFCE-63290A5CD538 Q30411811-3AB7AF82-6DD9-409D-955A-69F1F000C31A Q30415832-3CE8B5CE-0E3C-4106-B778-737B7ABBA393 Q31116556-6329516F-581E-4380-ADC8-50C8D49C19CA Q33162775-949BC778-DF1F-4ABF-A8C3-3F95857647CA Q33422634-31200A05-D0F3-436A-976C-8A34ACCFC386 Q33428648-BE45C4D7-3CB6-4C6E-91D1-9D79F1732062 Q33429717-8CF09B34-D9AC-401B-BB2D-78E9037C6535 Q33431168-512652A2-DF34-4EE7-8F49-795435B310A9 Q33593181-D4A7AA1D-EC3C-4A9B-AC0C-09C5FB1653DA Q33595144-21C6AA47-A64F-4ECF-8AE4-3E2ED43A534F Q33646367-FF477BBD-D301-4D96-AFDF-DE0B48F03BED Q33763918-9498AFDA-8E7C-468F-BDB8-B9AE7F684721 Q33820797-7A7BA11B-6B22-463A-9093-D17A4F8F9ADC Q33895624-87A7E3D3-E9F6-4694-B4FA-68B363E4A256 Q34234928-BC96C148-46D6-4890-BC5E-EBF3631B8898 Q34246244-2F778353-B764-4336-A240-9CCC0851A33C Q34499551-AA929A11-8F95-4426-888F-62D7BF8D9403 Q34584811-8BBD55D9-A318-40DB-9C71-A5E481609235 Q34667668-8F10EEEA-FA04-4B87-845E-74617F611A6F Q34803620-8BAB6044-3F0A-4F47-87B4-A295CF9B253A Q35530203-28809D87-EB48-497F-B2B9-E9DDA48E2682 Q35572060-D0B1EB52-A32A-4F6E-BED1-CAFA747CB61B Q35718077-D4689BF8-4755-46C0-8504-CA93FF720C31 Q35750692-9F1422D1-32C4-454B-8D4D-4501560436BD Q35824265-6AF04560-0DA0-42F9-B527-8F37BCBF0526 Q35967483-0DAF7AA4-2000-4545-93C2-09C100B0D5E7 Q36009950-B697F623-2180-447A-B9CB-831BE6F981D0 Q36105656-82D0D002-1BAB-4BC7-B456-A142BA21B7F7 Q36115829-B0FA96AA-7E2D-4279-ADBD-D693FCBD9BAD Q36369579-DEAEBDE2-6889-4A36-A2F9-90B509745D18 Q36621336-CEF54E82-671B-4DA8-9D94-DD8903469500 Q36765574-7D51172D-9D2F-415F-90C1-DE5A3631B5F3 Q36770084-F3925AD1-B719-4673-8F98-D86441A5C44A Q36786775-F6D51C45-E78C-40B4-85CD-7216C4217AAB Q36907276-FDEAA523-0FD3-4521-B6F5-969470598989 Q37005884-D21965D6-13DC-47A8-94AA-3238ACBEC3F6 Q37019668-E4C4796F-3AD3-4F84-B54D-CB23D54B24E3

P2860

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal

Item

http://www.wikidata.org/entity/Q34478729

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu